May 15th 2024
Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma.
February 27th 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL
January 12th 2024In an interview with Targeted Oncology, Franck Morschhauser, MD, PhD, discussed the high complete response rates and durable remissions seen with lisocabtagene maraleucel in patients with high-risk relapsed/refractory follicular lymphoma.
Read More
FDA Approves Mosunetuzumab-axgb for Relapsed/Refractory Follicular Lymphoma
December 23rd 2022In the pivotal phase 2 GO29781 study, the objective response rate and response durability was high, leading to the FDA approval of mosunetuzumab for the treatment of relapsed or refractory follicular lymphoma.
Read More
European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma
June 12th 2022The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies
Read More
Zanubrutinib Plus Obinutuzumab Elicits Improved Responses in Relapsed/Refractory Follicular Lymphoma
June 8th 2022The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.
Read More
Bispecific Antibody Triplet Regimen Induces 100% Response Rate in R/R FL
June 4th 2022Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.
Read More
Comparable Efficacy Profile Shown in Axi-cel and Tisa-Cel in Follicular Lymphoma
April 25th 2022Match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in the ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar outcomes in regard to efficacy between the 2 cellular therapies.
Read More
FDA Discourages Marketing Authorization for Zandelisib in Patients With FL or MZL
March 25th 2022The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.
Read More
Pola-G-Len Regimen Shows Promise as an Alternative to CAR T Cells in Refractory FL
December 10th 2021The combination of obinutuzumab with polatuzumab vedotin, or lenalidomide may be a solution for the toxicity sometimes observed with chimeric antigen receptor T cells in patients with follicular lymphoma.
Read More